Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perrotte, P.
Right arrow Articles by Dinney, C. P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perrotte, P.
Right arrow Articles by Dinney, C. P. N.
Clinical Cancer Research Vol. 5, 257-264, February 1999
© 1999 American Association for Cancer Research

Advances in Brief

Anti-epidermal Growth Factor Receptor Antibody C225 Inhibits Angiogenesis in Human Transitional Cell Carcinoma Growing Orthotopically in Nude Mice1

Paul Perrotte, Takashi Matsumoto, Keiji Inoue, Hiroki Kuniyasu, Beryl Y. Eve, Daniel J. Hicklin, Robert Radinsky and Colin P. N. Dinney2

Departments of Urology [P. P., C. P. N. D.] and Cancer Biology [T. M., K. I., H. K., B. Y. E., R. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and ImClone Systems, New York, New York [D. J. H.]

Epidermal growth factor receptor (EGFR) regulates the growth and progression of human transitional cell carcinoma (TCC) of the bladder. We have shown that therapy targeting EGFR inhibited the growth of human TCC established orthotopically in nude mice. The purpose of this study was to evaluate whether EGFR-directed therapy affects angiogenesis associated with the growth and metastasis of human TCC. We determined the cytostatic effect and the effect on production of angiogenic factors after in vitro treatment of the human TCC cell line 253J B-V with MAb C225, a chimerized monoclonal anti-EGFR antibody. The 253J B-V cells were implanted orthotopically into athymic nude mice, and established tumors (4 weeks) were treated with i.p. MAb C225. Expression of the angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF) was evaluated by immunohistochemistry and in situ mRNA hybridization analyses and correlated with microvessel density evaluated after immunohistochemical staining with anti-CD31. In vitro treatment with MAb C225 inhibited mRNA and protein production of VEGF, IL-8, and bFGF by 253J B-V cells in a dose-dependent manner. MAb C225 therapy of nude mice with established TCCs growing orthotopically resulted in inhibition of growth and metastasis compared with controls (P <0.0005). VEGF, IL-8, and bFGF expression was significantly lower in treated tumors than in controls. The down-regulation of these angiogenic factors preceded the involution of blood vessels. These studies indicate that therapy with anti-EGFR MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Choi, D. Sano, M. Cheung, M. Zhao, S. A. Jasser, A. J. Ryan, L. Mao, W.-T. Chen, A. K. El-Naggar, and J. N. Myers
Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model
Clin. Cancer Res., August 15, 2008; 14(16): 5081 - 5089.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al.
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. S. Hodkinson, A. MacKinnon, and T. Sethi
Targeting Growth Factors in Lung Cancer
Chest, May 1, 2008; 133(5): 1209 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Prewett, D. S. Deevi, R. Bassi, F. Fan, L. M. Ellis, D. J. Hicklin, and J. R. Tonra
Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab
Clin. Cancer Res., December 15, 2007; 13(24): 7432 - 7440.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al.
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and J. Tabernero
Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet
J. Clin. Oncol., October 10, 2007; 25(29): 4516 - 4518.
[Full Text] [PDF]

Home page
 JCOHome page
P. M. Harari, G. W. Allen, and J. A. Bonner
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Damiano, R. Caputo, S. Garofalo, R. Bianco, R. Rosa, G. Merola, T. Gelardi, L. Racioppi, G. Fontanini, S. De Placido, et al.
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
PNAS, July 24, 2007; 104(30): 12468 - 12473.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Wu, W. Yang, R. F. Barth, S. Kawabata, M. Swindall, A. K. Bandyopadhyaya, W. Tjarks, B. Khorsandi, T. E. Blue, A. K. Ferketich, et al.
Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab
Clin. Cancer Res., February 15, 2007; 13(4): 1260 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Shrader, M. S. Pino, G. Brown, P. Black, L. Adam, M. Bar-Eli, C. P.N. Dinney, and D. J. McConkey
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. P. Mitra, R. H. Datar, and R. J. Cote
Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification
J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H.-J. Lenz, E. Van Cutsem, S. Khambata-Ford, R. J. Mayer, P. Gold, P. Stella, B. Mirtsching, A. L. Cohn, A. W. Pippas, N. Azarnia, et al.
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
J. Clin. Oncol., October 20, 2006; 24(30): 4914 - 4921.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Jin, K. K. Iwata, A. Belldegrun, R. Figlin, A. Pantuck, Z.-F. Zhang, R. Lieberman, and J. Rao
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Mol. Cancer Ther., July 1, 2006; 5(7): 1754 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Vincenzi, D. Santini, A. Russo, M. Silletta, M. Gavasci, F. Battistoni, G. Di Cuonzo, L. Rocci, N. Gebbia, and G. Tonini
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
Ann. Onc., May 1, 2006; 17(5): 835 - 841.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms.
Cancer Res., March 15, 2006; 66(6): 3197 - 3204.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Folprecht, M. P. Lutz, P. Schoffski, T. Seufferlein, A. Nolting, P. Pollert, and C.-H. Kohne
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
Ann. Onc., March 1, 2006; 17(3): 450 - 456.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L Li, Y-Z Yuan, J Lu, L Xia, Y Zhu, Y-P Zhang, and M-M Qiao
Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice
Gut, February 1, 2006; 55(2): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kim, C. N. Prichard, M. N. Younes, Y. D. Yazici, S. A. Jasser, B. N. Bekele, and J. N. Myers
Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice
Clin. Cancer Res., January 15, 2006; 12(2): 600 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Segaert and E. Van Cutsem
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Ann. Onc., September 1, 2005; 16(9): 1425 - 1433.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. G. Christensen, P. W. Vincent, W. D. Klohs, D. W. Fry, W. R. Leopold, and W. L. Elliott
Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor
Mol. Cancer Ther., June 1, 2005; 4(6): 938 - 947.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Vallbohmer, W. Zhang, M. Gordon, D. Y. Yang, J. Yun, O. A. Press, K. E. Rhodes, A. E. Sherrod, S. Iqbal, K. D. Danenberg, et al.
Molecular Determinants of Cetuximab Efficacy
J. Clin. Oncol., May 20, 2005; 23(15): 3536 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. B. El-Abaseri, J. Fuhrman, C. Trempus, I. Shendrik, R. W. Tennant, and L. A. Hansen
Chemoprevention of UV Light-Induced Skin Tumorigenesis by Inhibition of the Epidermal Growth Factor Receptor
Cancer Res., May 1, 2005; 65(9): 3958 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Chinnaiyan, S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, S. A. Tomlins, A. M. Chinnaiyan, and P. M. Harari
Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva)
Cancer Res., April 15, 2005; 65(8): 3328 - 3335.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor
Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. K. Jain
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Science, January 7, 2005; 307(5706): 58 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Clin. Cancer Res., January 1, 2005; 11(1): 397 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P M Harari
Epidermal growth factor receptor inhibition strategies in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Skvortsov, B. Sarg, J. Loeffler-Ragg, I. Skvortsova, H. Lindner, H. Werner Ott, P. Lukas, K. Illmensee, and H. Zwierzina
Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment
Mol. Cancer Ther., December 1, 2004; 3(12): 1551 - 1558.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Potti and D. J. George
Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6371S - 6376S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Dominguez-Escrig, J. D. Kelly, D. E. Neal, S. M. King, and B. R. Davies
Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4874 - 4884.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Govindan
Cetuximab in Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 4241S - 4244S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, S. Guinn, and E. S. Vitetta
A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab')2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies
Clin. Cancer Res., May 15, 2004; 10(10): 3542 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Ke, X. Wen, Q.-P. Wu, S. Wallace, C. Charnsangavej, A. M. Stachowiak, C. L. Stephens, J. L. Abbruzzese, D. A. Podoloff, and C. Li
Imaging Taxane-Induced Tumor Apoptosis Using PEGylated, 111In-Labeled Annexin V
J. Nucl. Med., January 1, 2004; 45(1): 108 - 115.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Sosman
Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Uemura, H. Ishiguro, N. Nakaigawa, Y. Nagashima, Y. Miyoshi, K. Fujinami, A. Sakaguchi, and Y. Kubota
Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor
Mol. Cancer Ther., November 1, 2003; 2(11): 1139 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn and J. Baselga
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Grunwald and M. Hidalgo
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone
Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways
Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Abe, K. Terada, H. Wakimoto, R. Inoue, E. Tyminski, R. Bookstein, J. P. Basilion, and E. A. Chiocca
PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli
Cancer Res., May 1, 2003; 63(9): 2300 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. M. Veneziani, G. Fontanini, A. R. Bianco, et al.
Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase
Clin. Cancer Res., April 1, 2003; 9(4): 1546 - 1556.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler
Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice
Clin. Cancer Res., March 1, 2003; 9(3): 1200 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin
Docetaxel Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma
Clin. Cancer Res., February 1, 2003; 9(2): 886 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. M.L. Ebos, J. Tran, Z. Master, D. Dumont, J. V. Melo, E. Buchdunger, and R. S. Kerbel
Imatinib Mesylate (STI-571) Reduces Bcr-Abl-Mediated Vascular Endothelial Growth Factor Secretion in Chronic Myelogenous Leukemia
Mol. Cancer Res., December 1, 2002; 1(2): 89 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Kedar, C. H. Baker, J. J. Killion, C. P. N. Dinney, and I. J. Fidler
Blockade of the Epidermal Growth Factor Receptor Signaling Inhibits Angiogenesis Leading to Regression of Human Renal Cell Carcinoma Growing Orthotopically in Nude Mice
Clin. Cancer Res., November 1, 2002; 8(11): 3592 - 3600.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn
Targeting the Epidermal Growth Factor Receptor for Cancer Therapy
J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. H. Baker, D. Kedar, M. F. McCarty, R. Tsan, K. L. Weber, C. D. Bucana, and I. J. Fidler
Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-Associated Endothelial Cells for Therapy of Human Carcinomas
Am. J. Pathol., September 1, 2002; 161(3): 929 - 938.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Baselga
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Oncologist, August 15, 2002; 7(90004): 2 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-M. Huang, J. Li, E. A. Armstrong, and P. M. Harari
Modulation of Radiation Response and Tumor-induced Angiogenesis after Epidermal Growth Factor Receptor Inhibition by ZD1839 (Iressa)
Cancer Res., August 1, 2002; 62(15): 4300 - 4306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sweeney, T. Karashima, S.-J. Kim, D. Kedar, B. Mian, S. Huang, C. Baker, Z. Fan, D. J. Hicklin, C. A. Pettaway, et al.
Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production
Clin. Cancer Res., August 1, 2002; 8(8): 2714 - 2724.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin
Frequent Administration of Angiogenesis Inhibitor TNP-470 (AGM-1470) at an Optimal Biological Dose Inhibits Tumor Growth and Metastasis of Metastatic Human Transitional Cell Carcinoma in the Urinary Bladder
Clin. Cancer Res., July 1, 2002; 8(7): 2389 - 2398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Tedjarati, C. H. Baker, S. Apte, S. Huang, J. K. Wolf, J. J. Killion, and I. J. Fidler
Synergistic Therapy of Human Ovarian Carcinoma Implanted Orthotopically in Nude Mice by Optimal Biological Dose of Pegylated Interferon {alpha} Combined with Paclitaxel
Clin. Cancer Res., July 1, 2002; 8(7): 2413 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta
Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo
Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hirata, S.-i. Ogawa, T. Kometani, T. Kuwano, S. Naito, M. Kuwano, and M. Ono
ZD1839 (Iressa) Induces Antiangiogenic Effects through Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase
Cancer Res., May 1, 2002; 62(9): 2554 - 2560.
[Abstract] [Full Text] [PDF]

Home page